Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Data Bolsters Cosentyx In AS & PsA; Humira Head-To-Head Planned

Executive Summary

Novartis AG has unveiled fresh data supporting the efficacy of its Cosentyx (secukinumab) drug in ankylosing spondylitis and psoriatic arthritis along with plans to compare that front-running anti-IL-17A agent against AbbVie Inc.'s anti-TNF competitor Humira (adalimumab) in head-to-head clinical trials.

You may also be interested in...

Novartis' Cosentyx Boosted By High Psoriasis Skin Clearance Over 4 Years

Data showing Novartis' Cosentyx maintained high levels of skin clearance in psoriasis patients along with a favorable safety profile after four years should give the drug an advantage over new interleukin inhibitors undergoing Phase III trials in psoriasis.

Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors

Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts